Insmed, Inc. $INSM Holdings Raised by KLP Kapitalforvaltning AS

Key Points

• KLP Kapitalforvaltning AS increased its holdings in Insmed, Inc. by 10.5%, owning 37,800 shares valued at approximately $3.8 million as of the latest SEC filing.
• Insmed's stock has received multiple analyst upgrades, with several firms raising their target prices; notable adjustments include Jefferies increasing their price target from $129 to $148.
• Insmed reported a loss of ($1.70) EPS for the last quarter, missing analyst expectations, despite revenue rising by 18.9% year-over-year to $107.42 million.

KLP Kapitalforvaltning AS grew its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 10.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,800 shares of the biopharmaceutical company's stock after purchasing an additional 3,600 shares during the period. KLP Kapitalforvaltning AS's holdings in Insmed were worth $3,804,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Chung Wu Investment Group LLC purchased a new stake in Insmed in the 2nd quarter worth about $173,000. 111 Capital purchased a new stake in Insmed in the 2nd quarter worth about $237,000. Hilltop National Bank purchased a new stake in Insmed in the 2nd quarter worth about $28,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Insmed by 15.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,492 shares of the biopharmaceutical company's stock worth $754,000 after acquiring an additional 999 shares in the last quarter. Finally, Truist Financial Corp lifted its stake in Insmed by 3.1% in the 2nd quarter. Truist Financial Corp now owns 46,483 shares of the biopharmaceutical company's stock worth $4,678,000 after acquiring an additional 1,409 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on INSM. Cowen reissued a "buy" rating on shares of Insmed in a research note on Thursday, October 2nd. Jefferies Financial Group upped their target price on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Truist Financial upped their target price on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. JPMorgan Chase & Co. upped their target price on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 20th. Finally, Mizuho upped their target price on Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and an average price target of $149.06.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $162.33 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The firm has a market cap of $34.31 billion, a price-to-earnings ratio of -28.43 and a beta of 1.03. The business's 50-day simple moving average is $138.08 and its 200-day simple moving average is $101.82. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $164.58.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business's revenue was up 18.9% on a year-over-year basis. During the same period in the prior year, the company posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the transaction, the director directly owned 262,675 shares in the company, valued at approximately $38,190,318.25. This represents a 3.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 218,820 shares of company stock worth $28,232,955 in the last 90 days. Company insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.